|
10131
|
ACAM2000
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Emergent BioSolutions
|
2003
|
USA
|
Below 12 months of age
|
Single dose
|
Percutaneous
|
NA
|
Recombinant vaccinia viruses derived from replication-competent vaccinia strain
|
Lyophilized
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000
|
NA
|
|
10132
|
JYNNEOS
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Bavarian Nordic
|
NA
|
Denmark
|
18 years and above
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Vaccinia Virus Ankar
|
NA
|
US FDA
|
NA
|
NA
|
Imvamune, Imvanex, MVA-BN
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/jynneos
|
https://www.fda.gov/media/131078/download
|
|
10133
|
Aventis Pasteur Smallpox Vaccine
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
National Institute of Allergy and Infectious Diseases
|
2010
|
USA
|
18 - 32 years
|
NA
|
Percutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00038987
|
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda
|
https://clinicaltrials.gov/ct2/show/NCT00038987
|